Search

Chinese
Resource Library / Developing an ELISA for residual host cell proteins (HCPs)

podcast

Developing an ELISA for residual host cell proteins (HCPs)

In this podcast, we discuss tips for developing an ELISA for residual host cell proteins (or HCPs) for biopharmaceutical products using commercial kits with our special guest: Dr. Jeng-Dar Yang, Vice President of Biologics Development and Manufacturing Services at Frontage Laboratories, Inc.

Resource Preview

Resources to Consider

Left arrow
Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms
white-paper

Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms
The US Food and Drug Administration (FDA) issued new draft guidance in December 2016 indic...
Access Resource
Quantitation of Myostatin/GDF-8 in Human Serum Using ELISA
poster

Quantitation of Myostatin/GDF-8 in Human Serum Using ELISA
In this study, we validate the ELISA method and deem it to be suitable to quantify GDF8/My...
Access Resource
WebninarAnalytical Challenges for CMC Development of Cell and Gene Therapy ProductsWebninar
webinar

WebninarAnalytical Challenges for CMC Development of Cell and Gene...
In this webinar we will cover:
Innovative solutions and best practices for accelera...
Access Resource
Development and validation of an LC-MS/MS method for the quantification of fascin proteins in human serum
journal

Development and validation of an LC-MS/MS method for the...
Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion...
Access Resource
Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using the Simoa HD-X platform
poster

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...
Alzheimer’s disease (AD) is a neurodegenerative disorder which stands as one of the most...
Access Resource
Evaluating the feasibility of lyophilization for oral formulation development of monoclonal antibodies (mAbs)​
poster

Evaluating the feasibility of lyophilization for oral formulation...
Objective: To develop a stable lyophilized non-invasive oral formulation of monoclonal ant...
Access Resource
Companion Diagnostics for Alzheimer’s Disease
poster

Companion Diagnostics for Alzheimer’s Disease
Method Validation of Phospho-Tau217 (pTau-217) Quantitation Using the Quanterix Simoa™ ...
Access Resource
Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug Delivery System for Cannabinoids
poster

Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug...
This study is aimed at developing a Nanoemulsion formulation of a poorly water-soluble and...
Access Resource
A Competitive Ligand-binding Assay for the Detection of Neutralizing Antibodies Against XTMAB-16
poster

A Competitive Ligand-binding Assay for the Detection of Neutralizing...
Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with...
Access Resource
Validation of a 384 gene hybridization capture-based pharmacogenomics NGS panel: sensitivity, specificity, accuracy, and reproducibility in calling star alleles for drug metabolism genes
poster

Validation of a 384 gene hybridization capture-based pharmacogenomics...
​Frontage has developed a next-generation sequencing (NGS)-based method to rapidly deter...
Access Resource
Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug Development
panel-discussion

Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug...
Critical reagents – the key components used in LBA – are central to ensuring the consi...
Access Resource
General Practices for Critical Reagents Usage in Bioanalytical Labs
webinar

General Practices for Critical Reagents Usage in Bioanalytical Labs
In this webinar, Dr. Santosh Shah discusses the general industry standards for utilizing c...
Access Resource
Right arrow